{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:22:47Z","timestamp":1792783367733,"version":"4.5.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"University of Bergen","id":[{"id":"https:\/\/ror.org\/03zga2b32","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"DOI":"10.1007\/s11912-026-01833-z","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T03:58:57Z","timestamp":1789531137000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["What are the Unmet Needs in Managing Digestive Neuroendocrine Carcinomas?"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7132-6214","authenticated-orcid":false,"given":"Halfdan","family":"Sorbye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mair\u00e9ad G","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot ET","family":"Tesselaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Cives","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stian","family":"Knappskog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurel","family":"Perren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Strosberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"issue":"3","key":"1833_CR1","doi-asserted-by":"publisher","first-page":"e13249","DOI":"10.1111\/jne.13249","volume":"35","author":"H Sorbye","year":"2023","unstructured":"Sorbye H, Grande E, Pavel M, Tesselaar M, Fazio N, Reed NS, et al. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma. J Neuroendocrinol. 2023;35(3):e13249.","journal-title":"J Neuroendocrinol"},{"key":"1833_CR2","doi-asserted-by":"crossref","unstructured":"Eads JR, Halfdanarson TR, Asmis T, Bellizzi AM, Bergsland EK, Dasari A, et al. Expert consensus practice recommendations of the North American neuroendocrine tumor society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms. Endocrine-related Cancer. 2023;30(8):e220206.","DOI":"10.1530\/ERC-22-0206"},{"issue":"3","key":"1833_CR3","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/s41416-025-03054-w","volume":"133","author":"H Sorbye","year":"2025","unstructured":"Sorbye H, Hjortland GO, Vestermark LW, Ladekarl M, Svensson J, Sundlov A, et al. Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study. Br J Cancer. 2025;133(3):316\u201324.","journal-title":"Br J Cancer"},{"issue":"4","key":"1833_CR4","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1002\/cncr.31124","volume":"124","author":"A Dasari","year":"2018","unstructured":"Dasari A, Mehta K, Byers LA, Sorbye H, Yao JC. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases. Cancer. 2018;124(4):807\u201315.","journal-title":"Cancer"},{"issue":"9","key":"1833_CR5","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1159\/000511905","volume":"111","author":"H Elvebakken","year":"2021","unstructured":"Elvebakken H, Perren A, Scoazec JY, Tang LH, Federspiel B, Klimstra DS, et al. A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations. Neuroendocrinology. 2021;111(9):883\u201394.","journal-title":"Neuroendocrinology"},{"issue":"3","key":"1833_CR6","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1159\/000471880","volume":"105","author":"M Pavel","year":"2017","unstructured":"Pavel M, Valle JW, Eriksson B, Rinke A, Caplin M, Chen J, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents. Neuroendocrinology. 2017;105(3):266\u201380.","journal-title":"Neuroendocrinology"},{"issue":"1","key":"1833_CR7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1146\/annurev-pathmechdis-042524-023153","volume":"21","author":"Z Wang","year":"2026","unstructured":"Wang Z, Sun N, He J, Redin E, Rudin CM. Molecular Subtypes of Neuroendocrine Carcinoma: From Chaos to Consensus. Annu Rev Pathol. 2026;21(1):107\u201333.","journal-title":"Annu Rev Pathol"},{"issue":"6","key":"1833_CR8","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/cjp2.339","volume":"9","author":"AS Litmeyer","year":"2023","unstructured":"Litmeyer AS, Konukiewitz B, Kasajima A, Foersch S, Schicktanz F, Schmitt M, et al. High expression of insulinoma-associated protein 1 (INSM1) distinguishes colorectal mixed and pure neuroendocrine carcinomas from conventional adenocarcinomas with diffuse expression of synaptophysin. J Pathol Clin Res. 2023;9(6):498\u2013509.","journal-title":"J Pathol Clin Res"},{"issue":"1","key":"1833_CR9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00428-025-04241-z","volume":"488","author":"M Jesinghaus","year":"2026","unstructured":"Jesinghaus M, Schmitt MP, Foersch S, Konukiewitz B. MiNEN, amphicrine carcinomas, and conventional carcinomas with neuroendocrine differentiation: diagnostic criteria, open questions, and future perspectives. Virchows Archiv: Int J Pathol. 2026;488(1):33\u201343.","journal-title":"Virchows Archiv: Int J Pathol"},{"key":"1833_CR10","unstructured":"Tihy MSO, Oudijk L, Br\u00e4utigam K, et al. Multicentric ENETS morphological and molecular appraisal of high-grade gastroenteropancreatic neuroendocrine neoplasms (HG-GEP-NEN): Distinguishing NET G3 from NEC. 22nd Annual ENETS Conference 2025 2025:abstract 4455."},{"issue":"1","key":"1833_CR11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s12022-025-09885-w","volume":"36","author":"R Chen","year":"2025","unstructured":"Chen R, Tihy M, Lacroix L, de Rycke O, Lacombe C, Just PA, et al. Performance of Immunohistochemistry to Detect Rb\/p53 Alterations in High-Grade Neuroendocrine Neoplasms: Staining Patterns and Comparison with Genetic Testing. Endocr Pathol. 2025;36(1):40.","journal-title":"Endocr Pathol"},{"issue":"9","key":"1833_CR12","doi-asserted-by":"publisher","first-page":"e723","DOI":"10.1093\/oncolo\/oyad093","volume":"28","author":"M Liu","year":"2023","unstructured":"Liu M, Li N, Tang H, Chen L, Liu X, Wang Y, et al. The Mutational, Prognostic, and Therapeutic Landscape of Neuroendocrine Neoplasms. Oncologist. 2023;28(9):e723\u201336.","journal-title":"Oncologist"},{"issue":"1","key":"1833_CR13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13073-022-01018-w","volume":"14","author":"T Simon","year":"2022","unstructured":"Simon T, Riemer P, Jarosch A, Detjen K, Di Domenico A, Bormann F, et al. DNA methylation reveals distinct cells of origin for pancreatic neuroendocrine carcinomas and pancreatic neuroendocrine tumors. Genome Med. 2022;14(1):24.","journal-title":"Genome Med"},{"issue":"3","key":"1833_CR14","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1158\/2159-8290.CD-21-0669","volume":"12","author":"S Yachida","year":"2022","unstructured":"Yachida S, Totoki Y, Noe M, Nakatani Y, Horie M, Kawasaki K, et al. Comprehensive Genomic Profiling of Neuroendocrine Carcinomas of the Gastrointestinal System. Cancer Discov. 2022;12(3):692\u2013711.","journal-title":"Cancer Discov"},{"issue":"1","key":"1833_CR15","doi-asserted-by":"publisher","first-page":"9477","DOI":"10.1038\/s41467-025-65227-8","volume":"16","author":"B Goeppert","year":"2025","unstructured":"Goeppert B, Charbel A, Toth R, Zhang Y, Tabbakh D, Albrecht T, et al. DNA methylation patterns facilitate tracing the origin of neuroendocrine neoplasms. Nat Commun. 2025;16(1):9477.","journal-title":"Nat Commun"},{"key":"1833_CR16","doi-asserted-by":"publisher","first-page":"e2200336","DOI":"10.1200\/PO.22.00336","volume":"7","author":"S Knappskog","year":"2023","unstructured":"Knappskog S, Grob T, Venizelos A, Amstutz U, Hjortland GO, Lothe IM, et al. Mutation Spectrum in Liquid Versus Solid Biopsies From Patients With Advanced Gastroenteropancreatic Neuroendocrine Carcinoma. JCO Precis Oncol. 2023;7:e2200336.","journal-title":"JCO Precis Oncol"},{"issue":"10","key":"1833_CR17","doi-asserted-by":"publisher","first-page":"e230057","DOI":"10.1530\/ERC-23-0057","volume":"30","author":"A Venizelos","year":"2023","unstructured":"Venizelos A, Sorbye H, Elvebakken H, Perren A, Lothe IMB, Couvelard A, et al. Germline pathogenic variants in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2023;30(10):e230057.","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"1833_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/ERC-21-0152","volume":"29","author":"A Venizelos","year":"2021","unstructured":"Venizelos A, Elvebakken H, Perren A, Nikolaienko O, Deng W, Lothe IMB, et al. The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms. Endocrine-related Cancer. 2021;29(1):1\u201314.","journal-title":"Endocrine-related Cancer"},{"issue":"7","key":"1833_CR19","doi-asserted-by":"publisher","first-page":"e260170","DOI":"10.1530\/ERC-26-0170","volume":"33","author":"S Morken","year":"2026","unstructured":"Morken S, Sorbye H, Deng W, Dogramaci HT, Venizelos A, Weber Vestermark L, et al. Origin and evolution of colorectal mixed neuroendocrine-non-neuroendocrine neoplasms (MiNEN). Endocrine-related Cancer. 2026;33(7):e260170.","journal-title":"Endocrine-related Cancer"},{"issue":"7\u20138","key":"1833_CR20","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1159\/000503722","volume":"110","author":"A Busico","year":"2020","unstructured":"Busico A, Maisonneuve P, Prinzi N, Pusceddu S, Centonze G, Garzone G, et al. Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin. Neuroendocrinology. 2020;110(7\u20138):616\u201329.","journal-title":"Neuroendocrinology"},{"issue":"5","key":"1833_CR21","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/his.15002","volume":"83","author":"S Chen","year":"2023","unstructured":"Chen S, Sun L, Chen H, Li J, Lu C, Yang Y, et al. Clinicopathological and genetic characteristics of gastric neuroendocrine tumour (NET) G3 and comparisons with neuroendocrine carcinoma and NET G2. Histopathology. 2023;83(5):700\u201311.","journal-title":"Histopathology"},{"issue":"7463","key":"1833_CR22","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415\u201321.","journal-title":"Nature"},{"issue":"12","key":"1833_CR23","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1002\/cac2.12372","volume":"42","author":"H Wu","year":"2022","unstructured":"Wu H, Yu Z, Liu Y, Guo L, Teng L, Guo L, et al. Genomic characterization reveals distinct mutation landscapes and therapeutic implications in neuroendocrine carcinomas of the gastrointestinal tract. Cancer Commun (Lond). 2022;42(12):1367\u201386.","journal-title":"Cancer Commun (Lond)"},{"issue":"7793","key":"1833_CR24","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","volume":"578","author":"LB Alexandrov","year":"2020","unstructured":"Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Tian Ng AW, Wu Y, et al. The repertoire of mutational signatures in human cancer. Nature. 2020;578(7793):94\u2013101.","journal-title":"Nature"},{"issue":"4","key":"1833_CR25","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s12022-024-09827-y","volume":"35","author":"A Kasajima","year":"2024","unstructured":"Kasajima A, Pfarr N, Mayr EM, Ura A, Moser E, von Werder A, et al. Rapid Evolution of Metastases in Patients with Treated G3 Neuroendocrine Tumors Associated with NEC-Like Transformation and TP53 Mutation. Endocr Pathol. 2024;35(4):313\u201324.","journal-title":"Endocr Pathol"},{"issue":"1","key":"1833_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s12022-025-09869-w","volume":"36","author":"A Weiss","year":"2025","unstructured":"Weiss A, Teply-Szymanski J, Schmitt M, Foersch S, Jank P, Griger J, et al. Exploring Intratumoral Heterogeneity in Mixed Neuroendocrine-Nonneuroendocrine Neoplasms with Spatial Transcriptomics: Even More Diverse Than Anticipated. Endocr Pathol. 2025;36(1):29.","journal-title":"Endocr Pathol"},{"issue":"4","key":"1833_CR27","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1093\/oncolo\/oyab039","volume":"27","author":"A Dasari","year":"2022","unstructured":"Dasari A, Shen C, Devabhaktuni A, Nighot R, Sorbye H. Survival According to Primary Tumor Location, Stage, and Treatment Patterns in Locoregional Gastroenteropancreatic High-grade Neuroendocrine Carcinomas. Oncologist. 2022;27(4):299\u2013306.","journal-title":"Oncologist"},{"issue":"6","key":"1833_CR28","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.1245\/s10434-022-11477-5","volume":"29","author":"SR Kaslow","year":"2022","unstructured":"Kaslow SR, Vitiello GA, Prendergast K, Hani L, Cohen SM, Wolfgang C, et al. Surgical Treatment of Patients with Poorly Differentiated Pancreatic Neuroendocrine Carcinoma: An NCDB Analysis. Ann Surg Oncol. 2022;29(6):3522\u201331.","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"1833_CR29","doi-asserted-by":"publisher","first-page":"e2114180","DOI":"10.1001\/jamanetworkopen.2021.14180","volume":"4","author":"J Lin","year":"2021","unstructured":"Lin J, Zhao Y, Zhou Y, Tian Y, He Q, Lin J, et al. Comparison of Survival and Patterns of Recurrence in Gastric Neuroendocrine Carcinoma, Mixed Adenoneuroendocrine Carcinoma, and Adenocarcinoma. JAMA Netw Open. 2021;4(7):e2114180.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"1833_CR30","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1245\/s10434-019-07203-3","volume":"26","author":"AC Fields","year":"2019","unstructured":"Fields AC, Lu P, Vierra BM, Hu F, Irani J, Bleday R, et al. Survival in Patients with High-Grade Colorectal Neuroendocrine Carcinomas: The Role of Surgery and Chemotherapy. Ann Surg Oncol. 2019;26(4):1127\u201333.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"1833_CR31","doi-asserted-by":"publisher","first-page":"e126","DOI":"10.1097\/SLA.0000000000003562","volume":"274","author":"R Mao","year":"2021","unstructured":"Mao R, Li K, Cai JQ, Luo S, Turner M, Blazer D 3, et al. Adjuvant Chemotherapy Versus Observation Following Resection for Patients With Nonmetastatic Poorly Differentiated Colorectal Neuroendocrine Carcinomas. Ann Surg. 2021;274(2):e126\u201333.","journal-title":"Ann Surg"},{"issue":"5","key":"1833_CR32","doi-asserted-by":"publisher","first-page":"e12967","DOI":"10.1111\/jne.12967","volume":"33","author":"HC Pommergaard","year":"2021","unstructured":"Pommergaard HC, Nielsen K, Sorbye H, Federspiel B, Tabaksblat EM, Vestermark LW, et al. Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms. J Neuroendocrinol. 2021;33(5):e12967.","journal-title":"J Neuroendocrinol"},{"issue":"7","key":"1833_CR33","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1634\/theoncologist.2018-0382","volume":"24","author":"OB Alese","year":"2019","unstructured":"Alese OB, Jiang R, Shaib W, Wu C, Akce M, Behera M, et al. High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study. Oncologist. 2019;24(7):911\u201320.","journal-title":"Oncologist"},{"issue":"10","key":"1833_CR34","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1001\/jamaoncol.2022.3395","volume":"8","author":"C Morizane","year":"2022","unstructured":"Morizane C, Machida N, Honma Y, Okusaka T, Boku N, Kato K, et al. Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial. JAMA Oncol. 2022;8(10):1447\u201355.","journal-title":"JAMA Oncol"},{"issue":"8","key":"1833_CR35","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1007\/s00432-020-03214-w","volume":"146","author":"F Ma","year":"2020","unstructured":"Ma F, Wang B, Xue L, Kang W, Li Y, Li W, et al. Neoadjuvant chemotherapy improves the survival of patients with neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the stomach. J Cancer Res Clin Oncol. 2020;146(8):2135\u201342.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"12","key":"1833_CR36","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1016\/j.jtho.2017.09.1966","volume":"12","author":"L Xu","year":"2017","unstructured":"Xu L, Li Y, Liu X, Sun H, Zhang R, Zhang J, et al. Treatment Strategies and Prognostic Factors of Limited-Stage Primary Small Cell Carcinoma of the Esophagus. J Thorac Oncol. 2017;12(12):1834\u201344.","journal-title":"J Thorac Oncol"},{"issue":"16S","key":"1833_CR37","first-page":"3004","volume":"43","author":"JGV Capdevila","year":"2026","unstructured":"Capdevila JGV, Kuboki Y, Alese OB, Morgensztern D, Sayehli C, et al. Efficacy and safety of the DLL3\/CD3 T-cell engager obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression: Results from an ongoing phase I trial. J Clin Oncol. 2026;43(16S):3004.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1833_CR38","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1159\/000493318","volume":"108","author":"H Sorbye","year":"2019","unstructured":"Sorbye H, Baudin E, Borbath I, Caplin M, Chen J, Cwikla JB, et al. Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3). Neuroendocrinology. 2019;108(1):54\u201362.","journal-title":"Neuroendocrinology"},{"issue":"3","key":"1833_CR39","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.radonc.2013.01.008","volume":"106","author":"MB Meng","year":"2013","unstructured":"Meng MB, Zaorsky NG, Jiang C, Tian LJ, Wang HH, Liu CL, et al. Radiotherapy and chemotherapy are associated with improved outcomes over surgery and chemotherapy in the management of limited-stage small cell esophageal carcinoma. Radiotherapy oncology: J Eur Soc Therapeutic Radiol Oncol. 2013;106(3):317\u201322.","journal-title":"Radiotherapy oncology: J Eur Soc Therapeutic Radiol Oncol"},{"key":"1833_CR40","doi-asserted-by":"publisher","first-page":"102015","DOI":"10.1016\/j.eclinm.2023.102015","volume":"60","author":"MG McNamara","year":"2023","unstructured":"McNamara MG, Swain J, Craig Z, Sharma R, Faluyi O, Wadsley J, et al. NET-02: a randomised, non-comparative, phase II trial of nal-IRI\/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma. EClinicalMedicine. 2023;60:102015.","journal-title":"EClinicalMedicine"},{"issue":"3","key":"1833_CR41","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1470-2045(23)00001-3","volume":"24","author":"T Walter","year":"2023","unstructured":"Walter T, Lievre A, Coriat R, Malka D, Elhajbi F, Di Fiore F, et al. Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial. Lancet Oncol. 2023;24(3):297\u2013306.","journal-title":"Lancet Oncol"},{"key":"1833_CR42","doi-asserted-by":"publisher","unstructured":"Lamarca A, Walter T, Pavel M, Borbath I, Freis P, Nunez B, et al. Design and validation of the GI-NEC score to prognosticate overall survival in patients with high-grade gastrointestinal neuroendocrine carcinomas. J Natl Cancer Inst. 2017;109(5). https:\/\/doi.org\/10.1093\/jnci\/djw277","DOI":"10.1093\/jnci\/djw277"},{"issue":"4","key":"1833_CR43","doi-asserted-by":"publisher","first-page":"e13256","DOI":"10.1111\/jne.13256","volume":"35","author":"H Elvebakken","year":"2023","unstructured":"Elvebakken H, Hjortland GO, Garresori H, Andresen PA, Janssen EAM, Vintermyr OK, et al. Impact of KRAS and BRAF mutations on treatment efficacy and survival in high-grade gastroenteropancreatic neuroendocrine neoplasms. J Neuroendocrinol. 2023;35(4):e13256.","journal-title":"J Neuroendocrinol"},{"issue":"12","key":"1833_CR44","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1002\/ijc.70367","volume":"158","author":"S Morken","year":"2026","unstructured":"Morken S, Langer SW, Hjortland GO, Sundlov A, Hofsli E, Ladekarl M, et al. Molecular-clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas. Int J Cancer. 2026;158(12):3217\u201331.","journal-title":"Int J Cancer"},{"key":"1833_CR45","doi-asserted-by":"crossref","unstructured":"Borghesani M, Reni A, Lauricella E, Rossi A, Moscarda V, Trevisani E, et al. Efficacy and toxicity analysis of mFOLFIRINOX in high-grade gastroenteropancreatic neuroendocrine neoplasms. J Natl Compr Canc Netw. 2024;22(5):e247005.","DOI":"10.6004\/jnccn.2024.7005"},{"issue":"4","key":"1833_CR46","doi-asserted-by":"publisher","first-page":"e70168","DOI":"10.1111\/jne.70168","volume":"38","author":"BP Butt","year":"2026","unstructured":"Butt BP, Sorbye H, Ladekarl M, Stokmo HL, Lothe IMB, Fawad H, et al. Efficacy of FOLFIRINOX in digestive neuroendocrine carcinoma. J Neuroendocrinol. 2026;38(4):e70168.","journal-title":"J Neuroendocrinol"},{"issue":"4","key":"1833_CR47","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41416-024-02773-w","volume":"131","author":"H Elvebakken","year":"2024","unstructured":"Elvebakken H, Venizelos A, Perren A, Couvelard A, Lothe IMB, Hjortland GO, et al. Treatment outcome according to genetic tumour alterations and clinical characteristics in digestive high-grade neuroendocrine neoplasms. Br J Cancer. 2024;131(4):676\u201384.","journal-title":"Br J Cancer"},{"key":"1833_CR48","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ejca.2021.04.030","volume":"152","author":"J Hadoux","year":"2021","unstructured":"Hadoux J, Kanaan C, Durand A, Hescot S, Hautefeuille V, Cadiot G, et al. Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d\u2019Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network. Eur J Cancer. 2021;152:100\u201315.","journal-title":"Eur J Cancer"},{"issue":"1","key":"1833_CR49","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13046-023-02678-1","volume":"42","author":"J Chen","year":"2023","unstructured":"Chen J, Guanizo AC, Jakasekara WSN, Inampudi C, Luong Q, Garama DJ, et al. MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat. J Exp Clin Cancer Res. 2023;42(1):100.","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"1833_CR50","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.ccell.2024.05.002","volume":"42","author":"Z Wang","year":"2024","unstructured":"Wang Z, Liu C, Zheng S, Yao Y, Wang S, Wang X, et al. Molecular subtypes of neuroendocrine carcinomas: A cross-tissue classification framework based on five transcriptional regulators. Cancer Cell. 2024;42(6):1106\u201325. e8.","journal-title":"Cancer Cell"},{"issue":"10","key":"1833_CR51","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1158\/1078-0432.CCR-21-3058","volume":"28","author":"M Frizziero","year":"2022","unstructured":"Frizziero M, Kilgour E, Simpson KL, Rothwell DG, Moore DA, Frese KK, et al. Expanding Therapeutic Opportunities for Extrapulmonary Neuroendocrine Carcinoma. Clin cancer research: official J Am Association Cancer Res. 2022;28(10):1999\u20132019.","journal-title":"Clin cancer research: official J Am Association Cancer Res"},{"issue":"4","key":"1833_CR52","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1210\/endrev\/bnad006","volume":"44","author":"R Garcia-Carbonero","year":"2023","unstructured":"Garcia-Carbonero R, Anton-Pascual B, Modrego A, Del Carmen Riesco-Martinez M, Lens-Pardo A, Carretero-Puche C, et al. Advances in the Treatment of Gastroenteropancreatic Neuroendocrine Carcinomas: Are we Moving Forward? Endocr Rev. 2023;44(4):724\u201336.","journal-title":"Endocr Rev"},{"issue":"4","key":"1833_CR53","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1158\/1078-0432.CCR-19-1266","volume":"26","author":"J Capdevila","year":"2020","unstructured":"Capdevila J, Arques O, Hernandez Mora JR, Matito J, Caratu G, Mancuso FM, et al. Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas. Clin cancer research: official J Am Association Cancer Res. 2020;26(4):902\u20139.","journal-title":"Clin cancer research: official J Am Association Cancer Res"},{"key":"1833_CR54","doi-asserted-by":"publisher","first-page":"215799","DOI":"10.1016\/j.canlet.2022.215799","volume":"543","author":"Y Shimizu","year":"2022","unstructured":"Shimizu Y, Maruyama K, Suzuki M, Kawachi H, Low SK, Oh-Hara T, et al. Acquired resistance to BRAF inhibitors is mediated by BRAF splicing variants in BRAF V600E mutation-positive colorectal neuroendocrine carcinoma. Cancer Lett. 2022;543:215799.","journal-title":"Cancer Lett"},{"issue":"24","key":"1833_CR55","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa2501912","volume":"392","author":"E Elez","year":"2025","unstructured":"Elez E, Yoshino T, Shen L, Lonardi S, Van Cutsem E, Eng C, et al. Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer. N Engl J Med. 2025;392(24):2425\u201337.","journal-title":"N Engl J Med"},{"issue":"2","key":"1833_CR56","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1158\/1078-0432.CCR-21-2291","volume":"28","author":"G Boons","year":"2022","unstructured":"Boons G, Vandamme T, Marien L, Lybaert W, Roeyen G, Rondou T, et al. Longitudinal Copy-Number Alteration Analysis in Plasma Cell-Free DNA of Neuroendocrine Neoplasms is a Novel Specific Biomarker for Diagnosis, Prognosis, and Follow-up. Clin cancer research: official J Am Association Cancer Res. 2022;28(2):338\u201349.","journal-title":"Clin cancer research: official J Am Association Cancer Res"},{"issue":"S16","key":"1833_CR57","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.1200\/JCO.2024.42.16_suppl.4130","volume":"42","author":"MGPS McNamara","year":"2024","unstructured":"McNamara MGPS, Swain J, Halford MA, Sharma R, Faluyi OO, et al. The clinical utility of plasma cell-free DNA (cfDNA) in NET-02: Randomised, phase II trial of liposomal irinotecan (nal-IRI)\/5-fluorouracil (5-FU)\/folinic acid or docetaxel as second-line (2L) therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC). J Clin Oncol. 2024;42(S16):4130.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1833_CR58","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1200\/JCO.20.01055","volume":"39","author":"SV Liu","year":"2021","unstructured":"Liu SV, Reck M, Mansfield AS, Mok T, Scherpereel A, Reinmuth N, et al. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). J Clin Oncol. 2021;39(6):619\u201330.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1833_CR59","doi-asserted-by":"publisher","first-page":"e71809","DOI":"10.1002\/cam4.71809","volume":"15","author":"R Gujarathi","year":"2026","unstructured":"Gujarathi R, Kwock S, Abodunrin F, Setia N, Keutgen XM, Liao CY. Real World Outcomes With Chemotherapy and Immunotherapy in Metastatic Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinomas. Cancer Med. 2026;15(4):e71809.","journal-title":"Cancer Med"},{"issue":"9","key":"1833_CR60","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1038\/s41416-020-0775-0","volume":"122","author":"N Vijayvergia","year":"2020","unstructured":"Vijayvergia N, Dasari A, Deng M, Litwin S, Al-Toubah T, Alpaugh RK, et al. Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials. Br J Cancer. 2020;122(9):1309\u201314.","journal-title":"Br J Cancer"},{"issue":"3","key":"1833_CR61","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1530\/ERC-20-0382","volume":"28","author":"JC Yao","year":"2021","unstructured":"Yao JC, Strosberg J, Fazio N, Pavel ME, Bergsland E, Ruszniewski P, et al. Spartalizumab in metastatic, well\/poorly differentiated neuroendocrine neoplasms. Endocrine-related Cancer. 2021;28(3):161\u201372.","journal-title":"Endocrine-related Cancer"},{"issue":"17","key":"1833_CR62","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1002\/cncr.33591","volume":"127","author":"SP Patel","year":"2021","unstructured":"Patel SP, Mayerson E, Chae YK, Strosberg J, Wang J, Konda B, et al. A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort. Cancer. 2021;127(17):3194\u2013201.","journal-title":"Cancer"},{"issue":"12","key":"1833_CR63","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1200\/JCO-25-01657","volume":"44","author":"TP Walter","year":"2026","unstructured":"Walter TP, Mazieres J, Otto J, Lena H, Lepage C, Smith D, et al. Nivolumab +\/- Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial. J Clin Oncol. 2026;44(12):1120\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1833_CR64","doi-asserted-by":"publisher","first-page":"4891","DOI":"10.1038\/s41467-026-71155-y","volume":"17","author":"J Capdevila","year":"2026","unstructured":"Capdevila J, Hernando J, Molina-Cerillo J, Plana Serrahima M, Taberna Sanz M, Castelo B, et al. Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial. Nat Commun. 2026;17(1):4891.","journal-title":"Nat Commun"},{"issue":"1","key":"1833_CR65","doi-asserted-by":"publisher","first-page":"100364","DOI":"10.1016\/j.esmoop.2021.100364","volume":"7","author":"T Al-Toubah","year":"2022","unstructured":"Al-Toubah T, Halfdanarson T, Gile J, Morse B, Sommerer K, Strosberg J. Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms. ESMO Open. 2022;7(1):100364.","journal-title":"ESMO Open"},{"issue":"1","key":"1833_CR66","doi-asserted-by":"publisher","first-page":"6753","DOI":"10.1038\/s41467-024-50969-8","volume":"15","author":"MC Riesco-Martinez","year":"2024","unstructured":"Riesco-Martinez MC, Capdevila J, Alonso V, Jimenez-Fonseca P, Teule A, Grande E, et al. Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913). Nat Commun. 2024;15(1):6753.","journal-title":"Nat Commun"},{"issue":"6","key":"1833_CR67","doi-asserted-by":"publisher","first-page":"oyag140","DOI":"10.1093\/oncolo\/oyag140","volume":"31","author":"A Mandl","year":"2026","unstructured":"Mandl A, Chen R, Das S, Strosberg JR, Kasi A, Konda B, et al. Phase 2 study of cabozantinib (XL184) with nivolumab and ipilimumab for the treatment of poorly differentiated neuroendocrine carcinomas (ETCTN10315). Oncologist. 2026;31(6):oyag140.","journal-title":"Oncologist"},{"key":"1833_CR68","doi-asserted-by":"publisher","first-page":"104524","DOI":"10.1016\/j.critrevonc.2024.104524","volume":"204","author":"A Peddio","year":"2024","unstructured":"Peddio A, Pietroluongo E, Lamia MR, Luciano A, Caltavituro A, Buonaiuto R, et al. DLL3 as a potential diagnostic and therapeutic target in neuroendocrine neoplasms: A narrative review. Crit Rev Oncol Hematol. 2024;204:104524.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"1833_CR69","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s12022-025-09854-3","volume":"36","author":"M Schmitt","year":"2025","unstructured":"Schmitt M, Bohnenberger H, Bartsch DK, Wagner DC, Litmeyer AS, Grass A, et al. DLL3 Expression in Neuroendocrine Carcinomas and Neuroendocrine Tumours: Insights From a Multicentric Cohort of 1294 Pulmonary and Extrapulmonary Neuroendocrine Neoplasms. Endocr Pathol. 2025;36(1):9.","journal-title":"Endocr Pathol"},{"key":"1833_CR70","doi-asserted-by":"publisher","first-page":"e2500464","DOI":"10.1200\/PO-25-00464","volume":"9","author":"JS Ross","year":"2025","unstructured":"Ross JS, Thummalapalli R, Lacuna K, Aly RG, Baine MK, Rekhtman N, et al. Clinical and Pathologic Landscapes of Delta-Like Ligand 3 and Seizure-Related Homolog Protein 6 Expression in Neuroendocrine Carcinomas. JCO Precis Oncol. 2025;9:e2500464.","journal-title":"JCO Precis Oncol"},{"issue":"11","key":"1833_CR71","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1093\/oncolo\/oyac161","volume":"27","author":"J Yao","year":"2022","unstructured":"Yao J, Bergsland E, Aggarwal R, Aparicio A, Beltran H, Crabtree JS, et al. DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms. Oncologist. 2022;27(11):940\u201351.","journal-title":"Oncologist"},{"key":"1833_CR72","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1200\/JCO.2026.44.16_suppl.2642","volume":"44","author":"VWM Gambardella","year":"2026","unstructured":"Gambardella VWM, Kuboki Y, Alese OB, Morgensztern D, Sayehli C, et al. Analysis of delta-like ligand 3 (DLL3) expression levels and characteristics of patients (pts) with advanced extrapulmonary neuroendocrine carcinomas (epNECs) from an ongoing phase I trial. J Clin Oncol. 2026;44:2642.","journal-title":"J Clin Oncol"},{"issue":"27","key":"1833_CR73","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1200\/JCO-25-00363","volume":"43","author":"M Wermke","year":"2025","unstructured":"Wermke M, Gambardella V, Kuboki Y, Felip E, Sanmamed MF, Alese OB, et al. Phase I Dose-Escalation Results for the Delta-Like Ligand 3\/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3\u2009+\u2009Small Cell Lung Cancer or Neuroendocrine Carcinomas. J Clin Oncol. 2025;43(27):3021\u201331.","journal-title":"J Clin Oncol"},{"issue":"2S","key":"1833_CR74","first-page":"LB","volume":"14","author":"AMS Chauhan","year":"2026","unstructured":"Chauhan AMS, Custodio A, Vandamme T, Niccoli P, Kato K, et al. Phase I open-label dose-escalation\/-expansion study of first-line obrixtamig (BI 764532) plus chemotherapy in patients with DLL3-positive neuroendocrine carcinomas. Cancer Immunol Res. 2026;14(2S):LB\u2013A004.","journal-title":"Cancer Immunol Res"},{"issue":"S3","key":"1833_CR75","doi-asserted-by":"publisher","first-page":"106723","DOI":"10.1016\/j.esmoop.2026.106723","volume":"11","author":"JRS Mazieres","year":"2026","unstructured":"Mazieres JRS, Galot R, Sebastian M, Duruisseaux M, Morizane C, et al. A phase I dose escalation trial of obrixtamig\u2009+\u2009ezabenlimab in patients (pts) with small cell lung cancer (SCLC) or other neuroendocrine carcinomas (NECs) expressing DLL3. ESMO Open. 2026;11(S3):106723.","journal-title":"ESMO Open"},{"issue":"3","key":"1833_CR76","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/1750743X.2026.2652156","volume":"18","author":"B Koylu","year":"2026","unstructured":"Koylu B, Kikili CI, Kemik F, Demir N, Taskin OC, Durur Karakaya A, et al. Efficacy and safety of tarlatamab, a DLL3-targeted bispecific T-cell engager, in a patient with advanced esophageal small-cell neuroendocrine carcinoma: a case report. Immunotherapy. 2026;18(3):181\u20135.","journal-title":"Immunotherapy"},{"issue":"16S","key":"1833_CR77","first-page":"e20115","volume":"44","author":"TMCC Moore","year":"2026","unstructured":"Moore TMCC, Cannon S, Mauser JC, Jones E, Cass A, et al. Evaluation of atezolizumab, durvalumab, lurbinectedin, and tarlatamab in high-grade extrapulmonary neuroendocrine carcinoma: A multicenter retrospective comparative analysis. J Clin Oncol. 2026;44(16S):e20115.","journal-title":"J Clin Oncol"},{"issue":"16S","key":"1833_CR78","first-page":"4004","volume":"44","author":"HCA Beltran","year":"2026","unstructured":"Beltran HCA, Sankar K, Garmezy B, Jain P, BrownJR, et al. Efficacy and safety of the DLL3 T-cell engager gocatamig in participants (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN). J Clin Oncol. 2026;44(7S):182.","journal-title":"J Clin Oncol"},{"issue":"16S","key":"1833_CR79","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1200\/JCO.2026.44.16_suppl.4004","volume":"44","author":"CHHH Zhao","year":"2026","unstructured":"Zhao CHHH, Lu M, Mao C, Wang W, Yang J, et al. A randomized phase II dose optimization study for alveltamig (ZG006), a trispecific T-cell engager targeting DLL3\/DLL3\/CD3, as monotherapy in patients with refractory neuroendocrine carcinoma (ZG006-003). J Clin Oncol. 2026;44(16S):4004.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1833_CR80","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41698-021-00214-y","volume":"5","author":"AS Mansfield","year":"2021","unstructured":"Mansfield AS, Hong DS, Hann CL, Farago AF, Beltran H, Waqar SN, et al. A phase I\/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors. NPJ Precis Oncol. 2021;5(1):74.","journal-title":"NPJ Precis Oncol"},{"issue":"8","key":"1833_CR81","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1038\/s41591-026-04452-0","volume":"32","author":"LA Byers","year":"2026","unstructured":"Byers LA, Cho BC, Cooper AJ, Chiang AC, Han JY, Furqan M, et al. SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial. Nat Med. 2026;32(8):2898\u2013908.","journal-title":"Nat Med"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01833-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-026-01833-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01833-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:02:34Z","timestamp":1789534954000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-026-01833-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1833"],"URL":"https:\/\/doi.org\/10.1007\/s11912-026-01833-z","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"assertion":[{"value":"4 September 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HS: Research support from AAA\/Novartis. Advisory boards for BMS, Ipsen, Novartis, ITM, AAA, Boehinger Ingelheim, MSD. Lecture honoraria from Ipsen, SAM Nordic, Pierre Fabre, Daiichi Sankyo, Novartis. MMN: Research grant support from AstraZeneca, Servier, Ipsen and NuCana. Travel and accommodation support from AAA, Bayer and Ipsen. Speaker honoraria from Pfizer, Ipsen, NuCana, Mylan and AAA. Advisory boards for Celgene, Ipsen, Sirtex, Baxalta, Incyte and Astra Zeneca.METT: Grants from Merck and consulting fees from IPSEN and MSD.MC: Grants or consulting fees from Advanz, Curium, Esteve, Harbour Biomed, Harpoon Therapeutics, MSD and Ipsen. Speaker\u2019s fee from Istituto Gentili, Ipsen and Novartis.SK: Lecture honoraria from Novartis and Pfizer, and research funding from Pfizer, Astra Zeneca and Illumina.AP: Participated in Boehringer Ingelheim pathology workshops.JS. Consulting fees from Merck, Boehringer-Ingelheim, Exelixis, ITM and Curium.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human, or animal subjects performed by any of the authors.","order":2,"name":"Ethics","label":"Human and Animal Rights","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"95"}}